CytoDyn Inc.

CYDY·OTC Markets OTCQB·Healthcare
Compare
0.23000.0000 (0.00%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close0.2300
Open0.2245
Day range0.22000.2300
52-week range0.18000.4000
Off day high0.00%
Off 52-week high−42.50%
Volume240.71K
Avg. volume (3M)1.83M
Market cap337.99M
EPS (TTM)-0.0300
Forward P/E-1.28
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)1.71
Shares outstanding1.47B
Short interest—
Earnings dateJan 14, 2027 (est.)
Analyst target—
Profit margin0.00%

Against its peers

Compare in full ›
CYDY CTMX AGEN CHRS CGEM PYXS
Market cap 337.99M 512.06M 314.78M 131.36M 767.61M 198.30M
P/E (TTM) — — 2.8 — — —
Forward P/E -1.3 -5.0 -63.4 -1.3 -5.1 -1.5
Price/book -3.4 1.7 -1.5 2.2 2.5 9.2
Dividend yield — — — — — —
1-year change −8.00% −43.91% +81.51% −42.95% +69.93% −58.91%
Today 0.00% +7.80% +4.50% +5.54% −20.70% +1.22%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Related companies

Compare ›

The businesses closest to CytoDyn's by what they do, from their descriptions, with the same industry weighted in.

Company Mkt cap Price Today
CytomX Therapeutics, Inc.CTMX · Biotechnology 512.06M 2.3500 +7.80%
Agenus Inc.AGEN · Biotechnology 314.78M 6.97 +4.50%
Coherus Oncology, Inc.CHRS · Biotechnology 131.36M 0.8502 +5.54%
Cullinan Therapeutics, Inc.CGEM · Biotechnology 767.61M 12.49 −20.70%
Pyxis Oncology, Inc.PYXS · Biotechnology 198.30M 1.6600 +1.22%
Crescent Biopharma, Inc.CBIO · Biotechnology 513.37M 13.82 +5.82%
Corvus Pharmaceuticals, Inc.CRVS · Biotechnology 889.16M 10.57 +7.53%
Champions Oncology, Inc.CSBR · Biotechnology 67.23M 4.8300 0.00%

Also based in Vancouver, Washington, then elsewhere in Washington.

Company Mkt cap Price Today
Absci CorporationABSI · Vancouver, WA 1.80B 10.48 +4.80%
ZoomInfo Technologies Inc.GTM · Vancouver, WA 1.24B 4.2600 +0.47%
NWPX Infrastructure, Inc.NWPX · Vancouver, WA 885.29M 91.93 −4.42%
Barrett Business Services, Inc.BBSI · Vancouver, WA 802.18M 33.10 +1.13%
Riverview Bancorp, Inc.RVSB · Vancouver, WA 121.00M 6.13 +0.66%
Amazon.com, Inc.AMZN · Seattle, WAOdds 2.88T 266.03 +6.12%
Microsoft CorporationMSFT · Redmond, WAOdds 4.13T 555.80 +6.68%
Starbucks CorporationSBUX · Seattle, WAOdds 125.07B 109.70 +4.71%

What visitors to CytoDyn's page also look at.

Company Mkt cap Price Today
Vaxart, Inc.VXRT 97.48M 0.4000 0.00%
Co-Diagnostics, Inc.CODX 3.19M 0.3614 −4.89%
Sorrento Therapeutics, Inc.SRNE 165.38K 0.0003 0.00%
iBio, Inc.IBIO 51.45M 0.8000 −2.85%
Vir Biotechnology, Inc.VIR 1.99B 11.77 +4.90%

From the 4SEARCH.business instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 20 min.

Latest news

All CYDY news ›
markets.businessinsider.com··2 outletsPositive

CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026

Phase 2 CLOVER study enrolled 66 patients across seven sites in metastatic colorectal cancerUpdated data show universal CCR5 expression, early ctD... CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress…

METAINCY
More from 1 other outlet
markets.businessinsider.com·Positive

CytoDyn to Present at the LD Micro Invitational XVI

CFO Robert E. Hoffman to deliver company presentation on May 18 at 10 a.m. PT Presentation Date: Monday, May 18, 2026 Time: 10 a.m. PDT Link to view presentation: Webcast Link - LD Micro Invitational XVI. LD Micro is dedicated to being the…

DUOTMU
Stock Titan·Negative

CytoDyn names Robert E. Hoffman CEO effective Oct. 20

The compensation changes include a $525,000 salary and options for 2,500,000 shares, while CLOVER findings remain preliminary. The webcast adds a preliminary cross-cohort comparison from the Phase 2 CLOVER study: over weeks 0–4, median…

CYDYCTTHPFE
Stock Titan·Negative

CytoDyn quarterly net loss widens to $19.9M

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1933 For the transition period…

APLDXXIARCT
Stock Titan·

[EFFECT] CytoDyn Inc. SEC Filing

CytoDyn Inc. SEC Filing (Oct 8, 2026) Stock Titan [EFFECT] CytoDyn Inc. SEC Filing Sentiment and the balance of points Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The…

ARCTCYDY

From the 4Search news index, newest first.

In the news

16mentions in 30 days
16with it in the headline
Positivesentiment

Mentioned with

Cytodyn Inc10Amicus Therapeutics5Biomarin Pharmaceutical Inc.5Choo Chee Kong5Cytomed Therapeutics5Cytomed Therapeutics Ltd5EP Capital Inc.5The Board5

People in the coverage

Bradley L. Campbell5Choo Chee Kong5Eric Dube5Frank Knuettel II5Gary Lyons5Hoffman5

Themes

SEC Filings12Biotechnology10Healthcare98-K3Appoints3C-Suite3Ostx3People3

Most coverage from

  1. stocktitan.net7
  2. markets.businessinsider.com5
  3. seekingalpha.com2
  4. biospace.com1
  5. manilatimes.net1

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 16 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance